Arbutus Biopharma (ABUS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Arbutus Biopharma (ABUS) do?
Arbutus Biopharma Corp (ABUS) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops therapeutic drug candidates to treat chronic hepatitis B virus infections in clinical trials. The company develops combination therapies to treat chronic hepatitis B and licenses lipid nanoparticle delivery. It is worth $623.90M on the market and sold $181.37M over the last year.
- Market cap
- $623.90M
- P/E ratio
- 3.6×
- Annual sales
- $181.37M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 18, 2026
ABUS’s flags, in plain English
Each flag is a number from Arbutus Biopharma’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Low debt
Low debt, only 4% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Wide Gross Margin
Gross margin of 100% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Capital Works Hard
Earns 247.9% a year on the money it invests in the business. The money in the business, from shareholders and lenders together, earns a strong return. That points to a company that picks its investments well.
Profit with Caveats
Bottom-line profit of $220M in the 12 months to Sep 30, 2026, next to $147M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about ABUS
How big is Arbutus Biopharma?
Arbutus Biopharma’s market cap is $623.90M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $181.37M: what customers paid the company over the last year, before any costs.
What is ABUS’s P/E ratio?
ABUS’s P/E ratio is 3.6×. Investors pay about 3.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with ABUS?
The business generates no product sales and relies on clinical development milestones and licensing income to stay open. That is one risk on Arbutus Biopharma’s card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Arbutus Biopharma’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ABUS’s filings on SEC.gov. The Margin Monkey is research, not advice.
